Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung(Bone Health and Osteoporosis Foundation), Henry G. Bone(University of Arizona), José Zanchetta(Universidad del Salvador), Jacques P. Brown(Centre hospitalier de l'Université Laval), Michael A. Bolognese, Judy Maddox(Amgen (United States)), Leonid Katz(Amgen (United States)), Adolfo Díez‐Pérez(Tufts University), Steven Boonen(KU Leuven), Bente Langdahl(Aarhus University Hospital), Scott M. Wasserman(Amgen (United States)), Yuching Yang(Amgen (United States)), Andreas Grauer(Omeros Corporation (United States)), Jean‐Yves Reginster(University of Liège), Cesar Libanati(Amgen (United States))
Cited by 1,248
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k